# VALANX Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/valanx-biotech

- Industry: Biotechnology
- Headquarters: Vienna, Austria
- Website: www.valanx.bio
- Total disclosed funding: $0.1M
- Latest round: Seed (Jan 28, 2020)
- Investors on record: 2

## About

VALANX Biotech GmbH specializes in innovative protein conjugation technology, focusing on developing targeted biologics for therapeutic applications in immunology and oncology.Founded in 2017 in Austria, VALANX Biotech GmbH develops site-specific protein conjugation platforms. The latest funding round was a venture funding of EUR 3 mn from Fournier-Majoie Foundation, Fujifilm, Xista Science Ventures, Tecnet Equity, and SOSV on March 26, 2026. The company is led by Michael Lukesch, who has a history of founding companies in the biotech sector. The company is led by Michael Lukesch, who has a history of founding companies in the biotech sector.VALANX Biotech specializes in a novel site-specific protein conjugation platform that enables precise control over the conjugation site and the number of conjugations on proteins of interest. This technology is aimed at developing biologics, with potential applications in various therapeutic areas, including immunology and oncology. The company’s flagship product, GoldenSite™, facilitates the development of conjugates that enhance the efficacy and safety of therapeutic proteins. VALANX's client base includes pharmaceutical and biotechnology companies focused on innovative drug development, especially those interested in synthetic biology for precision medicine. The primary geographical markets for VALANX’s products extend across Europe and North America, targeting institutions engaged in advanced biomedical research and therapeutic development.VALANX Biotech generates revenue through partnerships and collaborations with pharmaceutical and biotech firms that utilize its protein conjugation technology for drug development. Transactions typically involve service agreements and licensing arrangements, where clients pay for access to the GoldenSite™ platform or contract VALANX for specific research and development services. The revenue structure includes fees associated with service contracts, which vary based on project scope and complexity. VALANX might also engage in milestone payments tied to the progress of specific projects and royalties from successful commercialization of products developed using its technology, focusing on delivering high-value scientific solutions to its clients. VALANX Biotech aims to carry out preclinical studies, finalize its antibody-drug candidate, and prepare for manufacturing. Plans include launching new product offerings to enhance therapeutic efficacy. The company is also targeting expansion into new markets across Europe and North America by 2022. The recent venture funding of EUR 3 mn will support these initiatives, allowing for the development of new product lines and the strengthening of market presence.

## Funding rounds

- Seed, Jan 28, 2020 — SOSV, RebelBio
- Seed, Apr 5, 2017, $0.1M — SOSV, RebelBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- RebelBio — Seed